Erratum: Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases (British Journal of Surgery (2014) 101 (613-621) DOI:10.1002/bjs.9465);Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases

British Journal of Surgery

Volumn 101, Issue 6, 2014, Pages 613-621

  Zech, C J ^a,c   Korpraphong, P ^d   Huppertz, A ^b   Denecke, T ^b   Kim, M J ^f   Tanomkiat, W ^e   Jonas, E ^g   Ba Ssalamah, A ^h  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d MAHIDOL UNIVERSITY   (Thailand)

^e PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^f Yonsei University College of Medicine   (South Korea)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; GADOXETIC ACID;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT CARE PLANNING; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT CARE PLANNING; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84898543042     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9594     Document Type: Erratum

References (28)

1. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al,.; Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17: 1225-1239.
2. Ballantyne GH, Quin J,. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 1993; 71 (Suppl): 4252-4266.
3. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE,. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586-589.
4. Wald C, Scheirey CD, Tran TM, Erbay N,. An update on imaging of colorectal cancer. Surg Clin North Am 2006; 86: 819-847.
5. Scheer A, Auer RA,. Surveillance after curative resection of colorectal cancer. Clin Colon Rectal Surg 2009; 22: 242-250.
6. Crucitti F, Sofo L, Doglietto GB, Bellantone R, Ratto C, Bossola M, et al,. Prognostic factors in colorectal cancer: current status and new trends. J Surg Oncol Suppl 1991; 2: 76-82.
7. LeGolvan MP, Resnick M,. Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors. J Surg Oncol 2010; 102: 898-908.
8. Pawlik TM, Choti MA,. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11: 1057-1077.
9. Cervone A, Sardi A, Conaway GL,. Intraoperative ultrasound (IOUS) is essential in the management of metastatic colorectal liver lesions. Am Surg 2000; 66: 611-615.
10. Conlon R, Jacobs M, Dasgupta D, Lodge JP,. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur J Ultrasound 2003; 16: 211-216.
11. Sietses C, Meijerink MR, Meijer S, van den Tol MP,. The impact of intraoperative ultrasonography on the surgical treatment of patients with colorectal liver metastases. Surg Endosc 2010; 24: 1917-1922.
12. Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, et al,. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31: 19-31.
13. Niekel MC, Bipat S, Stoker J,. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674-684.
14. Donati OF, Hany TF, Reiner CS, von Schulthess GK, Marincek B, Seifert B, et al,. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18-F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med 2010; 51: 692-699.
15. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R, et al,. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467.
16. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, et al.; European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275.
17. Lowenthal D, Zeile M, Lim WY, Wybranski C, Fischbach F, Wieners G, et al,. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 2011; 21: 832-840.
18. Muhi A, Ichikawa T, Motosugi U, Sou H, Nakajima H, Sano K, et al,. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2011; 34: 326-335.
19. Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE,. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18-F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol 2011; 46: 548-555.
20. Annemans L, Lencioni R, Warie H, Bartolozzi C, Ciceri M, Müller U,. Health economic evaluation of ferucarbotran-enhanced MRI in the diagnosis of liver metastases in colorectal cancer patients. Int J Colorectal Dis 2008; 23: 77-83.
21. Zech CJ, Grazioli L, Jonas E, Ekman M, Niebecker R, Gschwend S, et al,. Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. Eur Radiol 2009; 19 (Suppl 3): S753-S763.
22. Strasberg SM,. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005; 12: 351-355.
23. AptivSolutions®. ADDPLAN® 5 MC. Adaptive Designs-Plans and Analyses Release 5. http://www.aptivsolutions.com/addpdlan-software/ [accessed 24 September 2012 ].
24. Kieser M, Bauer P, Lehmacher W,. Inference on multiple endpoints in clinical trials with adaptive interim analyses. Biometrical Journal 1999; 41: 261-277.
25. Obuchowski NA,. On the comparison of correlated proportions for clustered data. Stat Med 1998; 17: 1495-1507.
26. Pawlik TM, Schulick RD, Choti MA,. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13: 51-64.
27. Bipat S, van Leeuwen MS, Ijzermans JN, Comans EF, Planting AS, Bossuyt PM, et al,. Evidence-base guideline on management of colorectal liver metastases in the Netherlands. Neth J Med 2007; 65: 5-14.
28. Mainenti PP, Mancini M, Mainolfi C, Camera L, Maurea S, Manchia A, et al,. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom Imaging 2010; 35: 511-521.